At the American Academy of Neurology 2024 annual meeting, Dr. Richard Nowak from Yale University discussed recent advancements in the therapeutic management of myasthenia gravis, such as the LUMINESCE phase 3 trial that assessed the efficacy and safety of satralizumab.
Read More: https://raredisease.pocn.com/treatment/recent-advances-in-myasthenia-gravis-treatment-highlighted-at-conference/
